In view of the risk of myocarditis in the ongoing COVID‐19 pandemic, it is essential to understand expression of membrane‐bound ACE2 in vulnerable subgroups such as heart failure patients and to assess the effects of pharmacological ACE inhibition. Here, ACE is linked to heart failure.